My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Paclitaxel (Taxol)
    Paclitaxel (Taxol)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1603
    CAS #: 33069-62-4Purity ≥98%

    Description: Paclitaxel (also known as NSC 125973; trade name taxol) is a highly potent microtubule polymer stabilizer (mitotic inhibitor that stabilizes the polymerization of tubulin) with IC50 of 0.1 pM in human endothelial cells. Paclitaxel has shown potent and a broad spectrum of antineoplastic activities that has been extensively used in the treatment of various cancers. It is a natural product isolated from the Pacific yew tree Taxus brevifolia that has anticancer activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2.

    References: Anticancer Drugs. 2003 Jan;14(1):13-9; Breast Cancer Res Treat. 2012 Aug;134(3):969-80. 

    Related CAS#: 117527-50-1 (Paclitaxel); 117527-50-1 (Paclitaxel-Succinic acid); 90332-63-1 (10-Deacetyl-7-xylosyl paclitaxel); 90332-66-4 (7-Xylosylpaclitaxel); 105454-04-4 (7-epi-Taxol); 114915-17-2 (7-Troc-paclitaxel); 199796-52-6 (DHA-paclitaxel, Taxoprexin); 263351-82-2 (Paclitaxel Poliglumex); unknown CAS # (Paclitaxel-SMCC, 7-O-(Amino-PEG4)- paclitaxel, 7-O-(Cbz-N-amido-PEG4)- paclitaxel, Paclitaxel-MVCP, MC-Val-Cit-PAB-Paclitaxel)


    Publications Citing Use of InvivoChem Paclitaxel (Taxol)

    1) J Med Chem. 2021 Apr 22;64(8):4498-4515. doi: 10.1021/acs.jmedchem.0c01837. Epub 2021 Mar 31. PMID: 33788562;

    2)  Eur J Med Chem. 2020 Sep 15;202:112519. doi: 10.1016/j.ejmech.2020.112519. 

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)853.91
    FormulaC47H51NO14 
    CAS No.33069-62-4
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 171 mg/mL (200.3 mM)
    Water:<1 mg/mL
    Ethanol: 18 mg/mL (21.1 mM)
    Solubility (In vivo)1% DMSO+30% polyethylene glycol+1% Tween 80: 30 mg/mL 
    Synonyms

    NSC 125973; NSC-125973; NSC125973 ;BMS 181339-01; BMS181339-01; BMS-181339-01; Trade name: Taxol; Taxol Konzentrat; Anzatax; Asotax; Bristaxol; Praxel; TAX.

    Chemical Name: (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate 

    SMILES Code: O=C1[[email protected]](OC(C)=O)C(C2(C)C)=C(C)[[email protected]@H](OC([[email protected]](O)[[email protected]@H](NC(C3=CC=CC=C3)=O)C4=CC=CC=C4)=O)C[[email protected]@]2(O)[[email protected]@H](OC(C5=CC=CC=C5)=O)[[email protected]@]6([H])[[email protected]@]1(C)[[email protected]@H](O)C[[email protected]@]7([H])OC[[email protected]]76OC(C)=O 

    Exact Mass: 853.33096 


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells.


    Cell Assay: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

    In VivoThe inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively.
    Animal modelFemale, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
    Formulation & DosageDissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.;  20 mg/kg; i.v. injection 
    References

    Anticancer Drugs. 2003 Jan;14(1):13-9; Breast Cancer Res Treat. 2012 Aug;134(3):969-80. 


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Paclitaxel 

    Paclitaxel



    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?